Thu.Oct 17, 2024

article thumbnail

STAT+: Medicare Advantage insurers ramped up use of technology to deny claims, Senate investigation shows

STAT

The nation’s three largest Medicare Advantage insurers increasingly refused to pay for rehabilitative care for seniors in the years after adopting sophisticated technologies to aid in their coverage decisions, a Senate investigation found. UnitedHealth Group, Humana, and CVS Health targeted denials among older adults who were requesting care in nursing homes, inpatient rehab hospitals, and long-term hospitals.

article thumbnail

Wave sees RNA editing validation in early trial results

PharmaVoice

The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: How invisible medical groups are powering telehealth’s GLP-1 ‘gold rush’

STAT

In the last two years, telehealth has gone all in on GLP-1s. Dozens of companies have started to offer the wildly popular obesity and diabetes medications, meeting patients who are flooding online for prescriptions that could help them lose as much as 20% of their body weight.  The telehealth GLP-1 boom wouldn’t be possible without clinicians willing to write prescriptions for those hundreds of thousands of patients.

article thumbnail

Vivan renews five-year lease at UK biotech hub White City Place

Pharma Times

The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma

136
136
article thumbnail

Navigating Payroll Compliance: Future-Proofing Payroll in an Evolving Regulatory Landscape

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

article thumbnail

Opinion: STAT+: Eli Lilly chief scientist Daniel M. Skovronsky: Beware elected leaders who would weaken patents

STAT

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You can also read Sandoz CEO Richard Saynor on what the 2024 conversation is missing and Bayer Pharmaceuticals COO Sebastian Guth on bad policy ideas.

More Trending

article thumbnail

STAT+: Former UnitedHealth doctors detail what changed at their clinics after takeovers

STAT

For three physicians, the changes were gradual, and then unmistakable, when UnitedHealth Group took over their practices. They lost control over their schedules, they were told to prioritize coding their patients’ illnesses , they felt like widgets. Those were the experiences of three former UnitedHealth doctors  — Susan Baumgaertel, Michael Good, and Rubin Hirsch — who spoke at STAT’s annual summit in Boston on Wednesday.

327
327
article thumbnail

After rejections, AbbVie secures approval for Parkinson’s drug

BioPharma Dive

Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.

136
136
article thumbnail

STAT+: For this cancer-focused digital health startup, an FDA rejection meant the end of the road

STAT

The bad news didn’t come all at once for Blue Note Therapeutics, but a final denial from the Food and Drug Administration in January proved to be the final blow. In late 2023, after a rejection from the agency earlier in the year, Blue Note had made a last ditch attempt to convince the FDA that Attune, its mental health app for cancer patients, could fill an urgent unmet need.

301
301
article thumbnail

As new Alzheimer’s biomarkers come into play, here’s where the money is going

PharmaVoice

The Alzheimer’s Drug Discovery Foundation has its finger on the pulse of diagnostics to add precision to the next wave of therapies.

130
130
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

More evidence on GLP-1s and opioid addiction

STAT

This story first appeared in The Readout newsletter.  Sign up for The Readout  and receive STAT’s award-winning biotech news delivered straight to your inbox.  Good morning. I had the unexpected opportunity to wake up a little too early today, not unlike the way Bristol Myers Squibb CEO Chris Boerner had the unexpected opportunity to testify in front of Bernie Sanders earlier this year.

article thumbnail

Sage to cut one-third of workforce, streamline drug pipeline

BioPharma Dive

The restructuring, which follows clinical setbacks in Alzheimer’s, Parkinson’s and tremor, will also involve the departure of five senior executives.

116
116
article thumbnail

Biotech veteran Tony Coles on partisan politics and fulfilling a promise to his co-founder

STAT

Veteran biotech executive Tony Coles has been the man behind the curtain of two multibillion-dollar acquisitions and many more boardroom discussions.  But, publicly, he has arguably been just as active pushing the drug industry and other business leaders towards difficult conversations on corporate responsibility and race. Those conversations, he told the crowd at the STAT Summit in Boston Thursday, have been much more difficult.

article thumbnail

Sanofi, expanding in radiopharma, strikes a joint venture deal

BioPharma Dive

The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for cancer under the Orano Med brand.

115
115
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

STAT+: Consumer and labor groups urge FTC to block Catalent sale to Novo Holdings

STAT

A coalition of unions, consumer groups and public interest organizations urged the Federal Trade Commission to challenge a $16.5 billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition will harm competition and reduce patient access to popular diabetes and weight loss medicines.

Diabetes 292
article thumbnail

First human skin atlas points way to healing without scars

pharmaphorum

The first human skin atlas is helping researchers to understand how skin forms, the mechanisms behind disorders, and could usher in scarless healing

115
115
article thumbnail

A race-based test for kidney function is finally changing. What about the rest of medicine?

STAT

Jazmin Evans was waiting on dialysis for four years before finally, on the Fourth of July last year, she received a kidney transplant. “Now I say the fireworks are for me,” said Evans, who was diagnosed with kidney disease when she was 17.  She would have been waiting even longer had it not been for a shift, in 2021, in the way that physicians calculate kidney function for Black patients like her.

289
289
article thumbnail

Regulatory considerations for biosimilar analytical similarity assessments

Drug Patent Watch

Regulatory Considerations for Biosimilar Analytical Similarity Assessments Biosimilars, or follow-on biologics, are biopharmaceuticals that are highly similar to an already approved biological product.

article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights

STAT

Why are biotech investors so interested in autoimmune disease? Who is behind the telehealth GLP-1 boom? And what were our favorite moments from the STAT Summit this week? We talk about all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about investors’ interest in using CAR-T to treat autoimmune conditions, the latest developments with the supply of Eli Lilly’s blockbuster weight loss drug, and the invisible m

288
288
article thumbnail

Sage cuts a third of its workforce after R&D setbacks

pharmaphorum

Sage has launched another round of layoffs as it deals with the fallout of dropping a key pipeline drug for Alzheimer's and Parkinson's

114
114
article thumbnail

STAT+: Alnylam’s CEO on welcoming competition, turning a profit, and a ‘spine-tingling moment’

STAT

For the last 20 years Alnylam Pharmaceuticals has converted Nobel-winning research on RNA-based gene-silencing into medicines, winning approvals for drugs delivered to the liver. That’s where some misfolded proteins are made, and in an increasingly diagnosed heart disease called ATTR cardiomyopathy, they eventually jam up muscles in the heart and contribute to heart failure.

article thumbnail

NICE backs first targeted therapy for ALK+ lung cancer

pharmaphorum

NICE backs NHS use of Roche's Alecensa as first adjuvant therapy for ALK+ NSCLC, and peri-operative use of MSD's Keytruda for all-comer NSCLC patients

105
105
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Opinion: STAT+: The biggest challenge facing the FDA’s new Rare Disease Innovation Hub

STAT

Over the summer, the Food and Drug Administration announced the creation of the Rare Disease Innovation Hub to serve as a point of collaboration and connectivity between the Center for Biologics Evaluation and Research (CBER), the Center for Drug Evaluation and Research (CDER), patient organizations, and product innovators with the goal of ultimately improving outcomes for patients.

article thumbnail

Union Commerce Minister Piyush Goyal holds meeting with pharmaceutical exporters to address industry concerns

Express Pharma

Union Commerce and Industry Minister Piyush Goyal recently convened a meeting with prominent stakeholders from the pharmaceutical industry to address the concerns of pharmaceutical exporters. The meeting, held on Wednesday, was attended by the General Secretary of the Indian Drug Manufacturers Association (IMDA), Mehul Shah, along with other key industry representatives.

104
104
article thumbnail

STAT+: Ballooning Medicaid costs challenge health insurer Elevance 

STAT

People who rely on Medicaid continue to get medical care at high rates, and it’s presenting a growing challenge for the major health insurers who cover them.  On Thursday, Elevance Health disclosed in its third quarter earnings release that its medical loss ratio — the amount of premium revenue it spent on medical care — was markedly higher than Wall Street analysts expected, sending its stock price into a tailspin.

266
266
article thumbnail

Zydus gains final USFDA approval for Fludrocortisone Acetate Tablets USP, 0.1 mg

Express Pharma

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Fludrocortisone Acetate Tablets USP, 0.1 mg (USRLD: Florinef Tablets, 0.1 mg). Fludrocortisone acetate tablets are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison’s disease and for the treatment of salt-losing adrenogenital syndrome.

102
102
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

DC Diagnosis: Bristol Myers CEO Chris Boerner on drug price negotiation and the election

STAT

Hello, and happy Thursday from Boston at the STAT Summit ! For those of you following along virtually, my co-author Sarah Owermohle is interviewing Atul Gawande, the assistant administrator of global health at USAID, this afternoon, and Bob Herman is interviewing former CMS administrator Don Berwick about the future of Medicare. Send news tips and your biggest outstanding election questions to rachel.cohrs@statnews.com.

article thumbnail

Lundbeck acquires Longboard Pharmaceuticals in $2.6 billion deal

Outsourcing Pharma

The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeckâs neuroscience pipeline.

99
article thumbnail

The GLP-1 telehealth boom, Senate investigation of MA plans, and the fall of a cancer startup

STAT

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.  Sign up to get it  delivered in your inbox every Tuesday and Thursday. The medical groups propping up the GLP-1 telehealth boom It’s relatively simple to go online and get a prescription for a GLP-1 medication for diabetes or obesity thanks to dozens of companies that have stepped in to fill demand for the potentially life-changing treatm

Diabetes 256